Related Experiment Videos
Neoadjuvant chemotherapy in 126 operable breast cancers
E Bélembaogo1, V Feillel, P Chollet
1Centre Jean Perrin and INSERM U71, Clermont-Ferrand, France.
European Journal of Cancer (Oxford, England : 1990)
|January 1, 1992
Summary
Induction chemotherapy significantly increased breast conservation rates in operable breast cancer patients. This approach, using doxorubicin, vincristine, cyclophosphamide, and 5-fluorouracil (AVCF), enabled breast-conserving therapy in 83% of cases, reducing the need for modified radical mastectomy.
Area of Science:
- Oncology
- Medical Research
Background:
- Operable breast cancer often necessitates modified radical mastectomy (MRM).
- Neoadjuvant chemotherapy is an alternative treatment strategy.
Purpose of the Study:
- To evaluate the efficacy of induction chemotherapy in increasing breast conservation rates.
- To assess the impact of chemotherapy regimen on treatment response.
Main Methods:
- 126 patients with non-inflammatory operable breast cancer received induction chemotherapy (AVCF, with methotrexate added in 80 cases).
- Tumor response was assessed by size reduction (>50%).
- Treatment outcomes included conservative surgery, radiotherapy, or MRM.
Main Results:
- 83% of patients (105/126) achieved >50% tumor shrinkage.
- Higher response rates were observed in aneuploid or high S-phase tumors, particularly with methotrexate.
- Breast conservation was achieved in 83% of cases, with only 19 undergoing MRM.
Conclusions:
- Primary induction chemotherapy significantly enhances breast conservation possibilities.
- This strategy reduces the extent of surgery required for operable breast cancer.
- Chemotherapy response is influenced by tumor ploidy and S-phase fraction.